In a presentation at the ACHEMA Pulse virtual conference this year, Emerson’s Alan Johnston shared how fast rollout of COVID vaccine manufacturing has changed the mindset of how quickly a new therapy can move from development to commercial manufacturing and ultimately to the consumer.
Emerson’s Alan Johnston shares how technology advances in real-time modeling, adaptive scheduling and predictive maintenance are enabling successes in optimization for biopharmaceutical manufacturers who may have a combination of both types of processes in their operations.
For pharmaceutical and biopharmaceutical manufacturers, the Life Sciences.NOW webinar series includes eight interactive discussions on digital plant technologies and will provide direction and updates on key manufacturing operation initiatives to improve operational performance, deliver cost effective quality and regulatory compliance and accelerate the product development pipeline.
Alan Johnston describes gene therapy, cell therapy and CAR-T which combines both. These have the goal to treat disease by changing the blueprint to our body at a microscopic level.
Pharma 4.0 is an initiative based on Industry 4.0, begun out of the International Society for Pharmaceutical Engineering Germany/Austria/Switzerland (ISPE D/A/CH) organization, which lead to the formation of: …the ISPE Pharma 4.0 special interest group (SIG) in 2017....
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Please do, Just link back to the post and send us a quick note so we can share your work. Thanks!
Our Global Community
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.